At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,110 enrolled
Drug / intervention
Vedolizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Special Drug-Use Surveillance Study on Entyvio for IV Infusion 300 mg [Ulcerative Colitis]
In Brief
An observational study evaluating Vedolizumab for Ulcerative Colitis. Completed, enrolled 1,110 participants across 1 site.
Detailed Summary
The purpose of this survey is to evaluate the long-term safety and effectiveness of vedolizumab for intravenous (IV) infusion 300 milligrams (mg) in ulcerative colitis (UC) patients in the routine clinical setting.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsUlcerative Colitis
CountriesJapan
Collaborators--
Timeline
N/ACompletedFinished
20192020202120222023202420252026
First PostedJan 2019
Enrollment StartFeb 2019
Primary CompletionFeb 2025
TodayJul 2026
First PostedJan 31, 2019
Enrollment StartFeb 1, 2019
Primary CompletionFeb 12, 2025
TodayJul 2, 2026
Enrollment to primary: 6.0 yearsPosted 7.4 years ago
Interventions
Vedolizumabdrug
Vedolizumab IV infusion